TORONTO–( BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved the milestone identified as Year 2 Q1 (v), as contemplated by the terms of a contribution agreement dated…


Previous articlePT282 – Rabbi Zac Kamenetz & The Rev. Hunt Priest – Judaism, Christianity, and Embracing Psychedelics
Next articlePsychedelic Bulletin: Big Pharma’s Foray Into Psychedelics; Psilocybin Trial Makes Headlines; Bill to Legalize Psilocybin in Washington State Filed